Pharming Group N.V. (PHAR) stock
PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.06−0.53 (-4.21%)
Close on Nov 17, 2026Market cap $846.23MP/E 301.5Yield –
Pharming operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $25.84M. The highest annual figure on record is $76.26M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.84M | – |
| FY2024 | Dec 31, 2024 | -$8.62M | – |
| FY2023 | Dec 31, 2023 | -$5.39M | -129.5% |
| FY2022 | Dec 31, 2022 | $18.23M | +34.5% |
| FY2021 | Dec 31, 2021 | $13.56M | -82.2% |
| FY2020 | Dec 31, 2020 | $76.26M | +11.7% |
| FY2019 | Dec 31, 2019 | $68.25M | – |
See a number that looks wrong?